bart cummings sage advice, page-6

Alex-You are so far from the real world in dealing with executive compensation and incentives that it is senseless to argue with you. You just don't want to face the facts.

Seriously, you should not be an investor in biotech, medical devices or start up companies. You should stick to mature companies where goals can be measured by share price increases and earnings from quarter to quarter and executives rewarded according to your formula.

UNI was a start up company in 2002 when it went public. It had a prototype device. In just six short years, and I do mean short for this industry, UNI has moved to a company with real products that are being sold and licenced for Real money. Now is the time to reward those who got UNI here.

The share price is depressed, no doubt, and for many reasons, none having to do with the CEO or management team. Some having to do with investor attitudes, such as yours, that don't want to give UNI credit for its significant accomplishments to date and the potential it has built for the futute.

Had UNI been a US company, the management would have been paid far higher and owned significantly more of an Equity stake from the beginning or the company would not have been able to attract quality, dedidcated managers who could have accomplished what UNI has to date. I venture to say that once UNI lists in the US, Alan's ability to lead, and to inspire investors, will drive UNI's price far higher than it is today.

If you are looking for someone to blame for UNI's low share price compared to its real value, look to yourself, your downramping management and the Australian investment community that can't seem to recognize value while they are tripping over it.